Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Sreek Vemulapalli and Roseann White explain the statistical challenges that can arise while collecting longer-term follow-up data during clinical trials.

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

Photo Credit: JACC Cardiovasc Interv. Central Illustration (adapted). Patients implanted with a mitral clip device that fails over the ensuing months or years can, if appropriately selected, safely ...

The writing committee says collaborative efforts and patient-level perspective can improve management of pain in this ...

While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

The data are observational but intuitive, say experts. Further work might define where T-TEER’s greatest benefit lies.

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.